Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Characterization of the Entner-Doudoroff pathway in <i>Pseudomonas aeruginosa</i> catheter-associated urinary tract infections.

Journal of bacteriology·2023

Same author

Characterization of the Entner-Douderoff Pathway in <i>Pseudomonas aeruginosa</i> Catheter-associated Urinary Tract Infections.

bioRxiv : the preprint server for biology·2023

Same author

Single-cell transcriptomic profiling reveals specific maturation signatures in human cardiomyocytes derived from <i>LMNB2</i>-inactivated induced pluripotent stem cells.

Frontiers in cell and developmental biology·2022

Same author

Increasing Tau 4R Tau Levels Exacerbates Hippocampal Tau Hyperphosphorylation in the hTau Model of Tauopathy but Also Tau Dephosphorylation Following Acute Systemic Inflammation.

Frontiers in immunology·2020

Same author

Reciprocal Regulation of PASTA Kinase Signaling by Differential Modification.

Journal of bacteriology·2019

Same author

Host suppression of quorum sensing during catheter-associated urinary tract infections.

Nature communications·2018

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Making stem cells infarct avid.

Ming Zhao¹, Matthew R Barron, Zhixin Li

¹Department of Biophysics, Medical College of Wisconsin, Milwaukee, USA. mzhao@mcw.edu <mzhao@mcw.edu>

Cell Transplantation

|November 3, 2009

Summary

Researchers engineered embryonic stem cells (ESCs) to bind to damaged heart tissue. This modification enhances stem cell retention at the infarcted site, improving potential for cardiac repair after heart attack.

More Related Videos

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Published on: March 30, 2022

Related Experiment Videos

Last Updated: Jun 19, 2026

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Published on: March 30, 2022

Area of Science:

Biomedical Engineering
Regenerative Medicine
Cell Biology

Background:

Low retention of transplanted stem cells in infarcted cardiac tissue limits therapeutic efficacy.
Embryonic stem cells (ESCs) hold promise for myocardial infarction repair but suffer poor engraftment.
Targeting dead and dying cells in the infarct zone is crucial for improving stem cell retention.

Purpose of the Study:

To engineer ESCs to specifically bind to infarcted cardiac tissue.
To enhance the retention of transplanted stem cells within the damaged myocardium.
To investigate a novel method for improving stem cell engraftment post-myocardial infarction.

Main Methods:

Modified mouse ESCs by attaching the C2A domain of synaptotagmin I to their surface via biotin-avidin coupling.
Engineered ESCs (C2A-ESCs) were designed to recognize phosphatidylserine (PS), a marker of apoptotic/necrotic cells.
In vitro assays assessed C2A-ESC binding to dying cardiomyocytes and evaluated cellular physiology (viability, pluripotency, differentiation).

Main Results:

Approximately 1 million C2A molecules were successfully conjugated per ESC surface under mild conditions.
C2A-ESCs demonstrated avid binding to dying, but not viable, cardiomyocytes in culture.
Surface modification did not compromise the viability, pluripotency, or differentiation potential of ESCs.

Conclusions:

Surface modification of ESCs with the C2A domain enables specific binding to dead/dying cardiac cells.
This approach significantly improves the ability of engineered stem cells to bind to infarcted tissue.
This strategy offers a promising method to enhance transplanted cell retention and may be applicable to other therapeutic cell types.